Results 1 to 10 of about 178,362 (241)

Severe acute axonal neuropathy following treatment with arsenic trioxide for acute promyelocytic leukemia: a case report [PDF]

Mediterranean Journal of Hematology and Infectious Diseases, 2016
Peripheral neuropathy is a common complication of arsenic toxicity. Symptoms are usually mild and reversible following discontinuation of treatment. A more severe chronic sensorimotor polyneuropathy characterized by distal axonal-loss neuropathy can be ...
Marcus Kuhn, Mithia Nabergoj, Kety Sammartin, Fabrizio Vianello   +3 more
doaj   +5 more sources

An overview of arsenic trioxide-involved combined treatment algorithms for leukemia: basic concepts and clinical implications

Cell Death Discovery, 2023
Arsenic trioxide is a first-line treatment drug for acute promyelocytic leukemia, which is also effective for other kinds of leukemia. Its side effects, however, limit its clinical application, especially for patients with complex leukemia symptoms ...
Yanan Jiang, Xiuyun Shen, Fengnan Zhi, Zhengchao Wen, Yang Gao, Juan Xu, Baofeng Yang, Yunlong Bai   +7 more
doaj   +2 more sources

Factors determining sensitivity and resistance of tumor cells to arsenic trioxide. [PDF]

PLoS ONE, 2012
Previously, arsenic trioxide showed impressive regression rates of acute promyelocytic leukemia. Here, we investigated molecular determinants of sensitivity and resistance of cell lines of different tumor types towards arsenic trioxide.
Serkan Sertel, Margaret Tome, Margaret M Briehl, Judith Bauer, Kai Hock, Peter K Plinkert, Thomas Efferth   +6 more
doaj   +1 more source

Hesperidin attenuates arsenic trioxide-induced cardiac toxicity in rats

Asian Pacific Journal of Tropical Biomedicine, 2023
Objective: To explore the cardioprotective effect of hesperidin against arsenic trioxide-induced cardiac toxicity in rats. Methods: Cardiac toxicity was induced by oral administration of 4 mg/kg arsenic trioxide for 30 days.
Gayatri Khuntia, Jeevan Ranjan Dash, Biswadeep Jena, Uma Kanta Mishra, Subash Chandra Parija   +4 more
doaj   +1 more source

Phase I/II trial of local interstitial chemotherapy with arsenic trioxide in patients with newly diagnosed glioma

Frontiers in Neurology, 2022
BackgroundGlioma is the most common primary brain tumor in adults with poor prognosis. The glioma patients benefit from STUPP strategy, including maximum and safe resection and adjuvant radiotherapy and chemotherapy.
Dayong Han, Dayong Han, Dayong Han, Lei Teng, Lei Teng, Lei Teng, Xiaoxiong Wang, Xiaoxiong Wang, Xiaoxiong Wang, Yunbo Zhen, Yunbo Zhen, Yunbo Zhen, Xiaofeng Chen, Xiaofeng Chen, Xiaofeng Chen, Mingchun Yang, Mingchun Yang, Mingchun Yang, Ming Gao, Ming Gao, Ming Gao, Guang Yang, Guang Yang, Guang Yang, Mingyang Han, Ligang Wang, Ligang Wang, Ligang Wang, Jiajun Xu, Jiajun Xu, Jiajun Xu, Yue Li, Alina Shumadalova, Shiguang Zhao, Shiguang Zhao, Shiguang Zhao, Shiguang Zhao   +36 more
doaj   +1 more source

UNC13B Promote Arsenic Trioxide Resistance in Chronic Lymphoid Leukemia Through Mitochondria Quality Control

Frontiers in Oncology, 2022
In clinical practice, arsenic trioxide can be used to treat a subset of R/R CML patients, but resistance tends to reappear quickly. We designed an experiment to study arsenic trioxide resistance in K-562 cells.
Xiao-Bo Wang, Li-Hua Yuan, Le-Ping Yan, Yong-Bin Ye, Bo Lu, Xiaojun Xu   +5 more
doaj   +1 more source

Arsenic induces functional re-expression of estrogen receptor α by demethylation of DNA in estrogen receptor-negative human breast cancer. [PDF]

PLoS ONE, 2012
Estrogen receptor α (ERα) is a marker predictive for response of breast cancers to endocrine therapy. About 30% of breast cancers, however, are hormone- independent because of lack of ERα expression. New strategies are needed for re-expression of ERα and
Juan Du, Nannan Zhou, Hongxia Liu, Fei Jiang, Yubang Wang, Chunyan Hu, Hong Qi, Caiyun Zhong, Xinru Wang, Zhong Li   +9 more
doaj   +1 more source

Arsenic trioxide sensitizes glioblastoma to a myc inhibitor. [PDF]

PLoS ONE, 2015
Glioblastoma multiforme (GBM) is associated with high mortality due to infiltrative growth and recurrence. Median survival of the patients is less than 15 months, increasing requirements for new therapies. We found that both arsenic trioxide and 10058F4,
Yayoi Yoshimura, Akihiko Shiino, Kazue Muraki, Tadateru Fukami, Shigeki Yamada, Takeshi Satow, Miyuki Fukuda, Masaaki Saiki, Masato Hojo, Susumu Miyamoto, Nobuyuki Onishi, Hideyuki Saya, Toshiro Inubushi, Kazuhiko Nozaki, Kenji Tanigaki   +14 more
doaj   +1 more source

The conformation change of Bcl-2 is involved in arsenic trioxide-induced apoptosis and inhibition of proliferation in SGC7901 human gastric cancer cells

World Journal of Surgical Oncology, 2010
Background Arsenic trioxide has been established as a first-line agent for treating acute promyelocytic leukemia. Experimental data suggest that arsenic trioxide also can have a potential use as chemotherapeutic agent for other malignancies.
Li Qiu, Ye Aifang, Zhou Mengtao, Zheng Yihu, Bai Yongheng, Zhang Qiyu   +5 more
doaj   +1 more source

Arsenic Trioxide: Pharmacological Applications

Vitae, 2023
Background: Arsenic trioxide is a chemical compound that has been used as a treatment for various diseases. Despite being potentially toxic, this compound has been used as a therapy to treat Acute Myeloid Leukemia and is being investigated as a possible ...
German Madrigal Redondo, María Fernanda Rojas Salas, Rolando Vargas Zúñiga, Daniela González Corrales, Celeste Ortega Monge, Pamela Ceciliano Porras, Mariana Cerdas Delgado, Jeison Montero Rivera   +7 more
doaj   +1 more source